AI-Powered scans aim to predict breast cancer remission without surgery
NCT ID NCT06708910
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a special type of scan (PET/MRI) combined with artificial intelligence can accurately tell if HER2-positive breast cancer has been completely eliminated after chemotherapy. Researchers will scan 460 women before, during, and after treatment, then compare the scan results with tissue samples taken during routine surgery. The goal is to see if the scan can reliably identify complete remission, potentially replacing some follow-up procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-FDG PET/MRI with artificial intelligence
What this could lead to
If successful, this could provide a non-invasive way to accurately assess treatment response in HER2-positive breast cancer, reducing the need for surgical biopsies.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not be accurate enough in real-world settings, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany